IP Library › Granted Patent US 7,951,312
Granted Patent B2
US 7,951,312 · App. 12/431,832 · Granted May 31, 2011

Borosilicate glass with UV-blocking properties for pharmaceutical packaging

Assignee: Schott AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,312
App. No.
12/431,832
Granted
May 31, 2011
Kind
B2
Abstract

The borosilicate glass for pharmaceutical packaging has a transmission τ in the visible range of more than 80% at a wavelength of 400 nm, a transmission τ in the UV range of at most 0.1% at wavelengths under 260 nm (each at a sample thickness of 1 mm), a transformation temperature Tg of 550° C. to 590° C. and a processing temperature V A of 1100° C. to 1200° C. The glass has a composition, in wt. % on an oxide basis, of SiO 2 , 60-80; B 2 O 3 , 5-15; Al 2 O 3 , 2-10; TiO 2 , 0.5-7; Σ Li 2 O+K 2 O+Na 2 O, 3-10; Σ alkaline earth oxides, 0.5-10; ZrO 2 , 0-3; and Fe 2 O 3 , 0-0.2. The glass is suitable for packaging UV-sensitive substances but nevertheless permits optical quality control.

Claims (92)

1. A borosilicate glass with UV-blocking properties for pharmaceutical packaging, said borosilicate glass comprising, in wt. % on the basis of oxide content:

SiO 2

60-80

B 2 O 3

8.2-15

Al 2 O 3

2-10

TiO 2

0.5-7

Σ Li 2 O + K 2 O + Na 2 O

3-10

Σ alkaline earth oxides

0.5-10

ZrO 2

0-3

Fe 2 O 3

0-0.2;

and a glass transition temperature Tg of 550° C. to 590° C., a processing temperature V A of 1100° C. to 1200° C. at a viscosity of 10 4 Pa s, a transmission π of at least 80% at a wavelength of 400 nm, and a transmission π of less than 0.1% at a wavelength of under 260 nm, each for a sample thickness of 1 mm, and

wherein the borosilicate glass is made by melting under oxidizing conditions.

2. The borosilicate glass as defined in claim 1 , containing from 0.5 to 5.5 wt. % of TiO 2 .

3. The borosilicate glass as defined in claim 1 , containing from 50 ppm to 1500 ppm of Fe 2 O 3 .

4. The borosilicate glass as defined in claim 1 , in which at least 80% of the TiO 2 present is in the +4 oxidation state.

5. The borosilicate glass as defined in claim 1 , which is refined with As 2 O 3 and/or Sb 2 O 3 as refining agent.

6. The borosilicate glass as defined in claim 1 , further comprising up to 1 wt. % of F.

7. The borosilicate glass as defined in claim 1 , wherein Fe 2 O 3 is present and a molar ratio of Fe 2 O 3 to TiO 2 is greater than ⅙.

8. The borosilicate glass as defined in claim 1 , further comprising from 0 to 3 wt. % of Bi 2 O 3 , 0 to 1 wt. % of WO 3 , and from 0 to 1 wt. % of MoO 3 .

9. A borosilicate glass with UV-blocking properties for pharmaceutical packaging, said borosilicate glass comprising in wt. %:

SiO 2

69-77

B 2 O 3

10-12

Al 2 O 3

3.5-6

TiO 2

0.1-7

Na 2 O

6-8

CaO

1-2.5

Σ Li 2 O + K 2 O + Na 2 O

3-10

Σ alkaline earth oxides

0.5-10

ZrO 2

0-1

F

0.20-1

Fe 2 O 3

0-1500 ppm;

and a glass transition temperature Tg of 550° C. to 590° C., a processing temperature V A of 1100° C. to 1200° C. at a viscosity of 10 4 Pa s, a transmission π of at least 80% at a wavelength of 400 nm, and a transmission π of less than 0.1% at a wavelength of under 260 nm, each for a sample thickness of 1 mm, and

wherein the borosilicate glass is made by melting under oxidizing conditions.

10. The borosilicate glass as defined in claim 1 , containing, in wt. %:

SiO 2

67-75

B 2 O 3

8.2-10

Al 2 O 3

3-7

TiO 2

0.5-4.5

Na 2 O

5.5-8

CaO

0.5-2

BaO

1-3

ZrO 2

0-1

F

0.20-1

Fe 2 O 3

50 ppm-1500 ppm.

11. A pharmaceutical package for a pharmaceutical preparation, said pharmaceutical package comprising a borosilicate glass with UV-blocking properties for pharmaceutical packaging, said borosilicate glass comprising, in wt. % on the basis of oxide content:

SiO 2

60-80

B 2 O 3

8.2-15

Al 2 O 3

2-10

TiO 2

0.5-7

Σ Li 2 O + K 2 O + Na 2 O

3-10

Σ alkaline earth oxides

0.5-10

ZrO 2

0-3

Fe 2 O 3

0-0.2;

and a glass transition Tg of 550° C. to 590° C., a processing temperature V A of 1100° C. to 1200° C. at a viscosity of 10 4 Pa s, a transmission π of at least 80% at a wavelength of 400 nm, and a transmission π of less than 0.1% at a wavelength of under 260 nm, each for a sample thickness of 1 mm, and

wherein the borosilicate glass is made by melting under oxidizing conditions.

12. The pharmaceutical package as defined in claim 11 , wherein said borosilicate glass contains from 0.5 to 4.5 wt. % of TiO 2 and from 50 ppm to 1500 ppm of Fe 2 O 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2009
From: OTT, FRANZ; FECHNER, JOERG HINRICH; RASTER, MAX; MAENNL, REINHARD
To: SCHOTT AG
Reel/Frame 023174/0747 →
Priority Claims (1)
DE 10 2008 001 496 · Apr 30, 2008 · national
Continuity (1)
Related Publication 20090315002A1 · Dec 24, 2009